Zambon Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Vicenza Italy (1878)

Organization Overview

First Clinical Trial
1997
NCT00205647
First Marketed Drug
1996
fosfomycin (monurol)
First NDA Approval
1996
fosfomycin (monurol)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Zambon SpA | ZAMBON SPA

Indications

Approved Indications


 

Cystitis

Prostatitis

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 2)

Aspergillosis (Phase 1)

Aspergillosis, Allergic Bronchopulmonary (Phase 1)

Asthma (Phase 2)

Atrophy (Phase 2)

Bronchiectasis (Phase 3)

Bronchitis (Phase 4)

Bronchitis, Chronic (Phase 4)

Chronic Disease (Phase 4)

Chronic Pain (Phase 4)

Dyskinesia, Drug-Induced (Phase 3)

Dyskinesias (Phase 3)

Fibrosis (Phase 3)

Idiopathic Pulmonary Fibrosis (Phase 3)

Joint Diseases (Phase 4)

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Multiple System Atrophy (Phase 2)

Parkinson Disease (Phase 4)

Pulmonary Aspergillosis (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Pulmonary Fibrosis (Phase 3)

Respiratory Tract Diseases (Phase 3)

Shy-Drager Syndrome (Phase 2)

Temporomandibular Joint Disorders (Phase 4)

Temporomandibular Joint Dysfunction Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial APIs: 23